Status:
COMPLETED
Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?
Lead Sponsor:
Radboud University Medical Center
Conditions:
Cardiovascular Disease
Ischemia-Reperfusion Injury
Eligibility:
MALE
18-50 years
Phase:
PHASE4
Brief Summary
The purpose of this project is to explore the interaction between caffeine and dipyridamole on ischemia-reperfusion injury in the forearm.
Detailed Description
Dipyridamole has been proven to reduce targeting of Annexin A5 in responses to ischemic exercise, indicating protection against ischemia-reperfusion injury in humans (pharmacological preconditioning)....
Eligibility Criteria
Inclusion
- Male
- Age between 18-50yr.
Exclusion
- cardiovascular disease
- hypertension (systole \> 140 mmHg, diastole \> 90 mmHg)
- hypercholesterolemia (random total cholesterol \> 6.5 mmol/l)
- diabetes mellitus (fasting glucose \> 7.0 mmol/L or random glucose \> 11.0 mmol/L)
- asthma (recurrent episodes of dyspnea and wheezing, or usage of prescribed inhalation medication: i.e. corticosteroids or B2-agonists)
- participation in any clinical trial during the last 60 days prior to this study.
- administration of two doses of Annexin A5 (0,1mg; 450MBq) during the last 5 years prior to this study.
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00430170
Start Date
January 1 2007
End Date
April 1 2007
Last Update
July 29 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500hb